padsevonil + ethinyl estradiol + levonorgestrel

Padsevonil + ethinyl estradiol + levonorgestrel is a hypothetical combination drug that would contain three active pharmaceutical ingredients: padsevonil (an investigational antiepileptic drug), ethinyl estradiol (a synthetic estrogen commonly used in oral contraceptives), and levonorgestrel (a synthetic progestin, also common in contraceptives). Padsevonil is a first-in-class antiseizure medication with a dual mechanism: it binds presynaptically to all isoforms of synaptic vesicle protein 2 (SV2A, SV2B, SV2C) and postsynaptically to the benzodiazepine recognition site of the GABAA receptor, partially agonizing it, thereby modulating both excitatory and inhibitory neurotransmission[1][2][3][5]. Ethinyl estradiol and levonorgestrel act as synthetic analogues of endogenous female sex hormones to suppress ovulation, alter the endometrium and cervical mucus to prevent pregnancy, and are primarily used for contraceptive purposes. No reports or evidence were found for the existence or clinical use of this specific combination.